Growth hormone-releasing hormone in normal aging: An update

G. R. Merriam, M. Kletke, S. Barsness, D. Buchner, V. Hirth, K. E. Moe, R. S. Schwartz, M. V. Vitiello

Research output: Contribution to journalReview article

Abstract

Muscle mass, strength, and aerobic capacity all decline with aging, ultimately leading to an increased risk of falls and impaired ability to live independently. Several pharmacological approaches, including androgen and growth hormone (GH) therapy, have been suggested as offering promise in counteracting this decline in functional capacity. Recently, administration of a growth hormone secretagogue such as growth hormone-releasing hormone (GHRH) has been explored as a possible alternative to GH for use in this application. The aging pituitary remains responsive to GHRH, and GHRH treatment may be a more physiological approach to enhancing GH levels. There are still relatively few controlled prospective studies of the effects of GH or GH secretagogues in aging, but preliminary results of short-term studies demonstrate an increase in lean body mass, decreased fat mass, and modest increases in bone mineral density. GHRH(1-29)NH2 (sermorelin acetate, Geref®), which is FDA-approved for the treatment of pediatric GH deficiency, has shown preliminary promise in several studies in healthy seniors. Follow-up studies currently underway are assessing the effects of once-daily dosing of subcutaneous sermorelin on hormonal and functional endpoints in normal older adults. Early results show that this treatment is well tolerated by aging subjects, and can increase 24-hour GH secretion, boost circulating levels of insulin-like growth factor-I, and improve body composition. However, much larger-scale prevention studies will be required to fully document the safety of chronic GH secretagogue therapy, and its efficacy in achieving such outcomes as reducing falls or fractures, or prolonging the capacity for independent living.

Original languageEnglish (US)
Pages (from-to)335-354
Number of pages20
JournalToday's Therapeutic Trends
Volume18
Issue number4
StatePublished - Jan 1 2000

Fingerprint

Growth Hormone-Releasing Hormone
Growth Hormone
Sermorelin
Independent Living
Therapeutics
Muscle Strength
Body Composition
Insulin-Like Growth Factor I
Bone Density
Androgens
Fats
Prospective Studies
Pharmacology
Pediatrics
Safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Merriam, G. R., Kletke, M., Barsness, S., Buchner, D., Hirth, V., Moe, K. E., ... Vitiello, M. V. (2000). Growth hormone-releasing hormone in normal aging: An update. Today's Therapeutic Trends, 18(4), 335-354.

Growth hormone-releasing hormone in normal aging : An update. / Merriam, G. R.; Kletke, M.; Barsness, S.; Buchner, D.; Hirth, V.; Moe, K. E.; Schwartz, R. S.; Vitiello, M. V.

In: Today's Therapeutic Trends, Vol. 18, No. 4, 01.01.2000, p. 335-354.

Research output: Contribution to journalReview article

Merriam, GR, Kletke, M, Barsness, S, Buchner, D, Hirth, V, Moe, KE, Schwartz, RS & Vitiello, MV 2000, 'Growth hormone-releasing hormone in normal aging: An update', Today's Therapeutic Trends, vol. 18, no. 4, pp. 335-354.
Merriam GR, Kletke M, Barsness S, Buchner D, Hirth V, Moe KE et al. Growth hormone-releasing hormone in normal aging: An update. Today's Therapeutic Trends. 2000 Jan 1;18(4):335-354.
Merriam, G. R. ; Kletke, M. ; Barsness, S. ; Buchner, D. ; Hirth, V. ; Moe, K. E. ; Schwartz, R. S. ; Vitiello, M. V. / Growth hormone-releasing hormone in normal aging : An update. In: Today's Therapeutic Trends. 2000 ; Vol. 18, No. 4. pp. 335-354.
@article{16c3bb1b7aa74493a7b20c28c4bcfb66,
title = "Growth hormone-releasing hormone in normal aging: An update",
abstract = "Muscle mass, strength, and aerobic capacity all decline with aging, ultimately leading to an increased risk of falls and impaired ability to live independently. Several pharmacological approaches, including androgen and growth hormone (GH) therapy, have been suggested as offering promise in counteracting this decline in functional capacity. Recently, administration of a growth hormone secretagogue such as growth hormone-releasing hormone (GHRH) has been explored as a possible alternative to GH for use in this application. The aging pituitary remains responsive to GHRH, and GHRH treatment may be a more physiological approach to enhancing GH levels. There are still relatively few controlled prospective studies of the effects of GH or GH secretagogues in aging, but preliminary results of short-term studies demonstrate an increase in lean body mass, decreased fat mass, and modest increases in bone mineral density. GHRH(1-29)NH2 (sermorelin acetate, Geref{\circledR}), which is FDA-approved for the treatment of pediatric GH deficiency, has shown preliminary promise in several studies in healthy seniors. Follow-up studies currently underway are assessing the effects of once-daily dosing of subcutaneous sermorelin on hormonal and functional endpoints in normal older adults. Early results show that this treatment is well tolerated by aging subjects, and can increase 24-hour GH secretion, boost circulating levels of insulin-like growth factor-I, and improve body composition. However, much larger-scale prevention studies will be required to fully document the safety of chronic GH secretagogue therapy, and its efficacy in achieving such outcomes as reducing falls or fractures, or prolonging the capacity for independent living.",
author = "Merriam, {G. R.} and M. Kletke and S. Barsness and D. Buchner and V. Hirth and Moe, {K. E.} and Schwartz, {R. S.} and Vitiello, {M. V.}",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "18",
pages = "335--354",
journal = "Today's Therapeutic Trends",
issn = "0741-2320",
publisher = "Communications Media for Education,Inc",
number = "4",

}

TY - JOUR

T1 - Growth hormone-releasing hormone in normal aging

T2 - An update

AU - Merriam, G. R.

AU - Kletke, M.

AU - Barsness, S.

AU - Buchner, D.

AU - Hirth, V.

AU - Moe, K. E.

AU - Schwartz, R. S.

AU - Vitiello, M. V.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Muscle mass, strength, and aerobic capacity all decline with aging, ultimately leading to an increased risk of falls and impaired ability to live independently. Several pharmacological approaches, including androgen and growth hormone (GH) therapy, have been suggested as offering promise in counteracting this decline in functional capacity. Recently, administration of a growth hormone secretagogue such as growth hormone-releasing hormone (GHRH) has been explored as a possible alternative to GH for use in this application. The aging pituitary remains responsive to GHRH, and GHRH treatment may be a more physiological approach to enhancing GH levels. There are still relatively few controlled prospective studies of the effects of GH or GH secretagogues in aging, but preliminary results of short-term studies demonstrate an increase in lean body mass, decreased fat mass, and modest increases in bone mineral density. GHRH(1-29)NH2 (sermorelin acetate, Geref®), which is FDA-approved for the treatment of pediatric GH deficiency, has shown preliminary promise in several studies in healthy seniors. Follow-up studies currently underway are assessing the effects of once-daily dosing of subcutaneous sermorelin on hormonal and functional endpoints in normal older adults. Early results show that this treatment is well tolerated by aging subjects, and can increase 24-hour GH secretion, boost circulating levels of insulin-like growth factor-I, and improve body composition. However, much larger-scale prevention studies will be required to fully document the safety of chronic GH secretagogue therapy, and its efficacy in achieving such outcomes as reducing falls or fractures, or prolonging the capacity for independent living.

AB - Muscle mass, strength, and aerobic capacity all decline with aging, ultimately leading to an increased risk of falls and impaired ability to live independently. Several pharmacological approaches, including androgen and growth hormone (GH) therapy, have been suggested as offering promise in counteracting this decline in functional capacity. Recently, administration of a growth hormone secretagogue such as growth hormone-releasing hormone (GHRH) has been explored as a possible alternative to GH for use in this application. The aging pituitary remains responsive to GHRH, and GHRH treatment may be a more physiological approach to enhancing GH levels. There are still relatively few controlled prospective studies of the effects of GH or GH secretagogues in aging, but preliminary results of short-term studies demonstrate an increase in lean body mass, decreased fat mass, and modest increases in bone mineral density. GHRH(1-29)NH2 (sermorelin acetate, Geref®), which is FDA-approved for the treatment of pediatric GH deficiency, has shown preliminary promise in several studies in healthy seniors. Follow-up studies currently underway are assessing the effects of once-daily dosing of subcutaneous sermorelin on hormonal and functional endpoints in normal older adults. Early results show that this treatment is well tolerated by aging subjects, and can increase 24-hour GH secretion, boost circulating levels of insulin-like growth factor-I, and improve body composition. However, much larger-scale prevention studies will be required to fully document the safety of chronic GH secretagogue therapy, and its efficacy in achieving such outcomes as reducing falls or fractures, or prolonging the capacity for independent living.

UR - http://www.scopus.com/inward/record.url?scp=0033670349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033670349&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0033670349

VL - 18

SP - 335

EP - 354

JO - Today's Therapeutic Trends

JF - Today's Therapeutic Trends

SN - 0741-2320

IS - 4

ER -